Scope and Claims Analysis for U.S. Patent 11,419,842 (Docetaxel–Human Serum Albumin Non-Covalent Complex, Clear Aqueous Solution, pH 5–8)
U.S. Patent 11,419,842 claims an injectable clear aqueous docetaxel–human serum albumin (HSA) composition in which docetaxel is present at concentrations above its aqueous solubility, docetaxel and HSA form a non-covalently bound complex, pH is 5 to 8, and specific preparation and ratio windows are used to maintain solution clarity and stability. Independent claim coverage is broad on formulation concept (complex + clear solution + pH window + “commercial pharmaceutical HSA for infusion”), while dependent claims narrow key operating parameters (ratio subranges, pH subrange, preparation steps, solvent removal, solution clarity duration, and specific cancer list for method-of-use).
What is U.S. Patent 11,419,842 claiming about docetaxel–HSA complex formulations?
Core subject matter (independent claims 1 and 7):
- A pharmaceutical composition that is a clear aqueous solution.
- The composition contains a non-covalently bound complex of:
- Docetaxel
- Human serum albumin (HSA)
- The docetaxel:HSA molar ratio is 0.1:1 to 5:1 (claim 1) or docetaxel:HSA weight ratio is 1:50 to 1:1000 (claim 7).
- The docetaxel concentration in the solution is higher than the aqueous solubility of docetaxel.
- The HSA source is limited to commercial pharmaceutical human serum albumin solution for infusion.
- The pH range is 5 to 8 (claims 1 and 7).
Claim 1: what does the “clear aqueous solution” and “non-covalently bound complex” require?
Claim 1 is structurally and functionally defined:
- Non-covalently bound complex language targets avoidance of covalent conjugates and bioconjugates formed via chemical linkage.
- The “clear aqueous solution” functional requirement narrows formulations that would otherwise precipitate (docetaxel is poorly soluble in water).
- The “docetaxel concentration higher than aqueous solubility” is a performance/threshold limitation. It implies the complexation is used to solubilize docetaxel beyond what would be expected in plain aqueous systems.
- The formulation is further constrained by pH 5–8 and use of infusion-grade commercial HSA.
Claim 7: how does weight-ratio coverage change the formulation space?
Claim 7 repeats the same conceptual scaffold (docetaxel–HSA, non-covalent complex, clear aqueous solution, above solubility, pH 5–8, HSA from infusion product), but uses:
- Weight ratio rather than molar ratio:
- 1:50 to 1:1000 (claim 7)
- With tighter dependent windows (claims 8–9).
- Adds “substantially free of solvent other than water” (claim 10) and “clear aqueous solution for at least 3 hours” (claim 11).
Practical effect: weight-ratio claim language can be harder to map to molar-ratio equivalents depending on assay definitions and specific HSA purity and spec range. Still, both claims aim at the same operable neighborhood: a docetaxel complex with HSA that yields a stable clear solution without relying on conventional solvents (or at least keeping co-solvents extremely low).
Which specific formulation parameters are the critical “claim tripwires” in 11,419,842?
The claims hinge on five parameter clusters:
-
Complex type
- “Non-covalently bound complex” excludes covalent albumin conjugates (e.g., chemical linkers).
- It also shapes how a competitor might argue absence of a complex versus mere co-administration.
-
Solubility/clarity performance
- “Clear aqueous solution” plus “docetaxel concentration higher than aqueous solubility” ties coverage to a solubilization effect that prevents precipitation.
-
pH window
- Broad: 5–8 (independent claims).
- Narrow: 5.5–7.5 (claim 4).
- Competitors attempting to move outside the window would reduce direct claim overlap for the pH-limited claims, but could still face doctrine-of-equivalents and independent-claim risk unless they exit both pH and other required elements.
-
Albumin source limitation
- “Commercial pharmaceutical human serum albumin solution for infusion” is a direct constraint.
- It ties coverage to using infusion-grade HSA product rather than laboratory-prepared HSA or alternative albumin forms.
-
Ratio windows
- Molar ratio in claim 1: 0.1:1 to 5:1
- Dependent narrowing:
- claim 2: 0.5:1 to 2:1
- claim 3: about 1:1
- Weight ratio in claim 7:
- claim 7: 1:50 to 1:1000
- claim 8: 1:60 to 1:300
- claim 9: 1:80 to 1:200
Net coverage logic: independent claims cover a formulation “box.” Dependent claims create additional “sub-boxes” that are tighter but still likely to fall within the independent claim concept.
How broad is claim 1 versus claim 7, and which is the better infringement hook?
Claim 1 (molar ratio-based)
- Pros for enforcement:
- Narrow ratio mapping uses molar definitions that can be directly tied to docetaxel and albumin molecular weights.
- Has a relatively broad molar range (0.1:1 to 5:1).
- Likely to be easier to argue for “above solubility” and “clear solution” for a broad array of formulation attempts.
Claim 7 (weight ratio-based)
- Pros for enforcement:
- Wide weight ratio range (1:50 to 1:1000) can accommodate formulations that differ in how docetaxel and albumin are quantified or specified.
- However, claim 7 adds more dependent constraints that can be used for alternative pleading strategies (claims 10–11 for solvent-free and duration of clarity).
Best infringement hook depends on the competitor’s label and formulation specs:
- If a competitor uses a fixed molar equivalent target, claim 1 aligns naturally.
- If a competitor controls and reports ratios by weight (or formulation documents align that way), claim 7 aligns.
What do the manufacturing claims (5–6) cover for docetaxel–HSA solution preparation?
Claim 5: specific preparation pathway
- Mixing:
- An organic solution of docetaxel in a polar water-miscible organic solvent
- A first aqueous solution containing HSA
- Result:
- forms a second aqueous solution
- where the second aqueous solution is a clear aqueous solution.
Claim 6: solvent removal
- Further comprising:
- removing the polar water-miscible organic solvent and water from the second aqueous solution.
Claim-scope implications for competitors
- The manufacturing claims protect a process of generating the clear complex-containing aqueous solution from an organic docetaxel solution and aqueous HSA, followed by solvent/water removal (as specified).
- A competitor using a wholly aqueous mixing protocol (no initial organic docetaxel solution) could attempt to avoid claim 5’s step sequence.
- A competitor that uses a different solvent system (non-water-miscible, or not “polar” / not “water-miscible”) could try to avoid claim 5’s solvent characterization.
How long must the solution remain clear under claim 11, and why does it matter?
Claim 11: clear aqueous solution for at least 3 hours
- This is a temporal stability limitation.
- In infringement analysis, this can become a key experimental battleground:
- competitor product testing conditions (temperature, container closure, agitation, light exposure) must match claim-relevant definitions used in the patent.
- If a competitor’s product sometimes forms haze/precipitate within that window, it can narrow or defeat a claim 11 theory while still potentially leaving exposure to claim 1 or claim 7 if those do not require a duration.
What method-of-use claims (12–13) cover, and how specific is the cancer list?
Claim 12: generic oncology treatment
- Administering a therapeutically effective amount of the composition of claim 1 to treat a cancer.
Claim 13: listed cancer types
- Breast cancer
- Non-small cell lung cancer
- Prostate cancer
- Gastric cancer
- Head and neck cancer
- Ovarian cancer
- Pancreatic cancer
- Kaposi’s sarcoma
Scope impact
- The method-of-use coverage is broad as to the treatment step but narrow by claim dependence to compositions of claim 1.
- Competitors targeting non-listed cancers could try to reduce method-of-use risk, but they would still face composition claim exposure if their product matches formulation requirements.
What patent landscape risk exists around docetaxel-albumin complex “clear aqueous” solutions in the US?
From the claims provided, the landscape risk profile is shaped by three groups of competing IP:
-
Docetaxel solvent-free or reduced-solvent formulations
- Historically, docetaxel is associated with solvent-based presentations (e.g., polysorbate-based systems).
- Claims that achieve clarity and solubilization without conventional solvents often attract dense follow-on IP: composition, ratios, pH, stability, and preparation.
-
Albumin binding and albumin complexation approaches
- Broad strategies include:
- non-covalent binding with albumin to increase solubility
- covalent albumin conjugation (generally not covered by “non-covalently bound”)
- The non-covalent limitation narrows the class of albumin-based solutions this patent reaches.
-
Manufacturing and stability patents
- Solvent selection, mixing sequence, and solvent removal are common patent targets.
- Stability-related claim additions like “clear for at least 3 hours” can create separate infringement pathways.
Enforcement posture likely
- Composition claims (1 and 7) provide primary coverage.
- Manufacturing claims (5–6) provide secondary hooks if a competitor’s product can be tied to that preparation pathway.
- Temporal clarity (11) gives additional specificity for litigating stability-driven differences.
- Method-of-use claims (12–13) are a backstop for label and indication alignment.
How do potential generic or biosimilar-like scenarios play out for a small-molecule docetaxel–HSA complex?
Docetaxel–HSA is not a biologic “biosimilar” in the classic sense, but the protein component can complicate manufacturing comparability. Competitive risk for a generic “entry” scenario focuses on:
- whether the generic can replicate:
- the non-covalent complex
- the above-solubility clear aqueous outcome
- the pH window
- the specific ratio ranges
- the use of infusion-grade commercial HSA
- the solvent profile (claim 10) and clarity duration (claim 11)
A product that falls outside pH or ratio ranges may still be challenged if the independent claim elements are satisfied. A product that uses covalent albumin conjugation could avoid the “non-covalently bound” limitation, but then it may not meet the “non-covalently bound complex” requirement.
What are the likely claim design choices in 11,419,842, and how do they affect claim construction?
Key construction levers likely used in litigation:
- “non-covalently bound complex” requires an evidentiary record that the complex exists as a binding interaction rather than physical dispersion.
- “clear aqueous solution” is typically a measurable property (clarity/visual or turbidity threshold).
- “docetaxel concentration higher than aqueous solubility” requires:
- defining the relevant aqueous solubility benchmark
- mapping lab conditions to the “aqueous solubility” definition referenced or implied in the patent.
- “human serum albumin … from commercial pharmaceutical human serum albumin solution for infusion” limits the source and may support arguments against albumin from different lots or processing specifications.
- “polar water-miscible organic solvent” in claim 5 creates room for dispute on solvent classification.
How does the dependent claim set broaden or narrow actual enforceable coverage?
Dependent formulations:
- claim 2 narrows molar ratio to 0.5:1 to 2:1
- claim 3 adds a target ratio “about 1:1”
- claim 4 narrows pH to 5.5–7.5
- claim 8 and 9 provide weight-ratio narrow windows
- claim 10 narrows solvent presence to “substantially free of solvent other than water”
- claim 11 adds time-based clarity: “at least 3 hours”
Dependent process coverage:
- claim 5 defines the mixing sequence and starting components (docetaxel in polar water-miscible organic solvent plus aqueous HSA)
- claim 6 defines removal of the organic solvent and water
Dependent clinical coverage:
- claim 12 and 13 define treatment context and a specific cancer list.
Enforcement strategy that follows claim structure:
- If a product matches independent claim 1’s formulation elements, claim 2–4 help narrow to additional subranges if needed.
- If product specs align with weight ratios, claim 7 plus claim 8–11 become the main battleground.
Key details extracted from the claim set (structured view)
| Claim |
Coverage type |
Binding/solution requirements |
Ratio requirements |
pH requirements |
Additional constraints |
| 1 |
Composition |
Non-covalently bound docetaxel-HSA complex; clear aqueous solution; docetaxel concentration above aqueous solubility; HSA from infusion product |
Molar ratio 0.1:1 to 5:1 |
5 to 8 |
Uses commercial pharmaceutical HSA for infusion |
| 2 |
Composition |
Same as claim 1 |
Molar ratio 0.5:1 to 2:1 |
Same |
|
| 3 |
Composition |
Same as claim 1 |
Molar ratio about 1:1 |
Same |
|
| 4 |
Composition |
Same as claim 1 |
Same |
5.5 to 7.5 |
|
| 5 |
Method (prep) |
Mix organic docetaxel solution (polar water-miscible solvent) + aqueous HSA to form second aqueous solution that is clear |
Not specified |
Not specified |
Clear aqueous outcome is requirement |
| 6 |
Method (prep) |
Removes polar water-miscible organic solvent and water |
Not specified |
Not specified |
|
| 7 |
Composition |
Non-covalently bound docetaxel-HSA complex; clear aqueous solution; docetaxel above aqueous solubility; HSA from infusion product |
Weight ratio 1:50 to 1:1000 |
5 to 8 |
|
| 8 |
Composition |
Same as claim 7 |
Weight ratio 1:60 to 1:300 |
Same |
|
| 9 |
Composition |
Same as claim 7 |
Weight ratio 1:80 to 1:200 |
Same |
|
| 10 |
Composition |
Same as claim 7 |
Same |
Same |
“Substantially free of solvent other than water” |
| 11 |
Composition |
Same as claim 7 |
Same |
Same |
Clear aqueous solution for at least 3 hours |
| 12 |
Method (treat) |
Administer claim 1 composition to treat cancer |
N/A |
N/A |
Therapeutically effective amount |
| 13 |
Method (treat) |
As claim 12 |
N/A |
N/A |
Cancer list: breast, NSCLC, prostate, gastric, head/neck, ovarian, pancreatic, Kaposi’s sarcoma |
What expiration and exclusivity timelines are relevant to 11,419,842?
No information in the prompt includes the patent’s filing date, priority date, term adjustments, maintenance status, or any Orange Book reference-listed drug. Without those details, an exclusivity or expiration timeline cannot be determined from the claims alone.
How strong is the claim set for invalidity and design-around, based on the provided language only?
Strength indicators in the provided claims
- Independent claims are tightly drafted around:
- a specific complex type (non-covalent)
- a specific solution state (clear aqueous)
- a measurable functional outcome (docetaxel above aqueous solubility)
- defined pH range
- defined albumin source (commercial infusion HSA)
- Dependent claims add multiple additional axes that can be used to prove infringement even if a competitor tries to vary one parameter (ratio or pH) while still meeting other elements.
Design-around indicators
- Move outside pH 5–8 to avoid independent claims.
- Use a different albumin type or source that does not meet “commercial pharmaceutical … for infusion.”
- Use covalent albumin conjugates rather than non-covalently bound complexes.
- Avoid “clear aqueous solution” at least during relevant evaluation.
- If pursuing method-of-prep avoidance: use different solvents or avoid the “docetaxel organic solution in polar water-miscible organic solvent” step, or avoid the specific mixing sequence.
Key Takeaways
- U.S. Patent 11,419,842 protects a non-covalent docetaxel–HSA complex formulated as a clear aqueous solution with docetaxel concentration above aqueous solubility, using infusion-grade commercial HSA, and a pH of 5 to 8.
- Independent claim 1 uses molar ratio 0.1:1 to 5:1; independent claim 7 uses weight ratio 1:50 to 1:1000, both anchored to the same solution and HSA sourcing limitations.
- The claim set creates multiple enforcement levers: pH subranges, ratio subranges, solvent-free constraint (“substantially free of solvent other than water”), and stability (“clear … for at least 3 hours”).
- Manufacturing claims cover a mixing-based preparation from an organic docetaxel solution in a polar water-miscible solvent plus aqueous HSA, followed by removal of solvent and water.
- Method-of-use claims cover treatment of specified cancers, with composition claim 1 as the predicate.
FAQs
1) Can a covalent albumin-docetaxel conjugate avoid infringement of 11,419,842?
If the conjugate is not “non-covalently bound” as required by the claims, it targets avoidance of an essential claim element.
2) Does 11,419,842 cover docetaxel–HSA solutions that are clear only initially but haze later?
Claim 11 specifically requires clarity for at least 3 hours; initial clarity alone may not satisfy claim 11, but claims 1 and 7 still require a “clear aqueous solution” (without an explicit time term).
3) How can a product differ from the patent on pH without changing other formulation elements?
Altering the formulation to fall outside pH 5 to 8 avoids the pH limitation in both independent composition claims and the dependent claim 4 range.
4) Are method-of-prep claims (5–6) relevant if a supplier argues they don’t control manufacturing?
They remain relevant for process infringement theories tied to the claimed manufacturing steps, especially if manufacturing records show use of a polar water-miscible organic docetaxel solution mixed with aqueous HSA.
5) What is the main commercial vulnerability created by the “commercial pharmaceutical HSA for infusion” limitation?
Using a non-infusion HSA source or a differently defined albumin preparation can be used to challenge a core claim limitation tied to the albumin starting material.
References (APA)
- U.S. Patent 11,419,842.
